Mouse polyclonal to SLITL2, Host Mouse
- Known as:
- Mouse pab SLITL2, Host Mouse
- Catalog number:
- YF-PA26822
- Product Quantity:
- 50 uL
- Category:
- -
- Supplier:
- Abfron
- Gene target:
- Mouse polyclonal SLITL2 Host
Related genes to: Mouse polyclonal to SLITL2, Host Mouse
- Gene:
- VASN NIH gene
- Name:
- vasorin
- Previous symbol:
- SLITL2
- Synonyms:
- -
- Chromosome:
- 16p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 2005-01-26
- Date modifiied:
- 2014-11-19
Related products to: Mouse polyclonal to SLITL2, Host Mouse
Related articles to: Mouse polyclonal to SLITL2, Host Mouse
- : Congenital pulmonary airway malformation (CPAM) is a rare developmental disorder characterized by cystic lung lesions, yet its extracellular matrix (ECM) composition remains poorly understood. This study employed decellularization and data-independent acquisition (DIA) proteomics to compare ECM profiles between cystic (CPAM) and histologically normal non-diseased (ND) regions from the lungs of four patients. : The decellularized scaffolds retained their native architecture with minimal residual DNA (<50 ng/mg). Proteomic analysis revealed 431 differentially expressed proteins (DEPs), with 171 upregulated and 260 downregulated in CPAM. Key findings revealed CPAM-specific enrichment of collagens (COL4A6, COL4A2, COL10A1, COL21A1 and PIIINP), glycoproteins (SPP1, FRAS1, FREM1, FREM2, LTBP1 and FBLN7), ECM regulators (TENM2, ROR2 and OMD), and ECM-affiliated proteins (ANXA7), alongside downregulation of glycoproteins (VASN and ABI3BP), proteoglycans (PODN and MXRA7), ECM regulators (SCARA5, PAPPA, SAA4, CPXM1, CTSC, THY1, SERPINA6/A1/D1, BSG, LYVE1, ITIH4 and CD44), and ECM-affiliated proteins (LGALSL). Pathway analysis highlighted the dysregulation of TGF-β, PI3K-AKT, and mTOR signaling in CPAM and aberrant ECM-cell interactions in pathogenesis. We also evaluated their functional properties and investigated the impact of ECM-based hydrogels on recellularization. : These findings provide a comprehensive proteomic atlas of CPAM ECM alterations, offering insights into disease mechanisms and potential therapeutic targets. - Source: PubMed
Publication date: 2026/08/30
Li YananYang PingYuan MiaoZhu XinglongMao ShengqiangYang YingYao MenglinChen FeiZhou YanyanBao JiXu ChangLi Yi - Study DesignRetrospective cohort study.ObjectiveTo compare long-term clinical and radiographic outcomes between the Bryan and ProDisc-C cervical disc prostheses following single-level cervical disc arthroplasty (CDA), with particular focus on sagittal alignment, motion behavior, heterotopic ossification (HO), and radiographic adjacent segment degeneration.MethodsThis retrospective single-center cohort study included patients who underwent single-level CDA with either the Bryan or ProDisc-C prosthesis between 2004 and 2014 and had complete minimum 10-year clinical and radiographic follow-up data. Clinical outcomes were evaluated using the Neck Disability Index (NDI), visual analog scale for neck and arm pain, and modified Japanese Orthopaedic Association (mJOA) score. Radiographic assessments included cervical lordosis, segmental and total range of motion (ROM), functional spinal unit (FSU) height, cervical sagittal vertical axis, T1 slope, HO according to the McAfee classification, and radiographic adjacent segment degeneration assessed using the Walraevens scoring system.ResultsA total of 71 patients were included, including 40 treated with the Bryan prosthesis and 31 treated with ProDisc-C. The median follow-up duration was 141 months [IQR, 123-173 months]. Both groups demonstrated significant improvements in VAS-N, VAS-A, NDI, and mJOA scores compared with preoperative baseline values, with no significant between-group differences at final follow-up. Radiographically, final index-level ROM was comparable between groups, although a within-group reduction from baseline was observed in the Bryan group. ProDisc-C was associated with greater index-level lordosis and higher measured FSU height at final follow-up. The incidence of radiographic adjacent segment degeneration was comparable between the Bryan and ProDisc-C groups. HO was more frequent in the ProDisc-C group, with differences in HO grade and distribution between the two prostheses. Revision rates were comparable between groups.ConclusionAt a minimum 10-year follow-up, Bryan and ProDisc-C CDA provided durable and comparable clinical outcomes after single-level surgery. Direct between-group comparisons showed differences in selected radiographic parameters, including index-level lordosis, measured FSU height, and HO characteristics, whereas final index-level ROM and radiographic adjacent segment degeneration were comparable. These findings suggest that implant-related radiographic differences may exist, but they did not translate into measurable differences in long-term clinical outcomes in this cohort. - Source: PubMed
Publication date: 2026/08/24
Sang DachengLi ZhenxuTian XueshiQu RuomuLi ShuyangYang XiaoxiongHu LishengZhao YanbinSun YuZhou Feifei - Vascular risk factors (VRFs) contribute to white matter microstructural degeneration, but their tract-specific contributions are unclear. We assessed the independent associations of four major VRFs with white matter microstructure in a large, multi-cohort study. - Source: PubMed
LeFevre James DVyas YuktiSathe AditiShashikumar NiranjanaPechman Kimberly RYang YisuDurant AlainaKanakaraj PraitayiniKim Michael EGao ChenyuNewlin Nancy RRamadass KarthikKhairi Nazirah MohdLi ZhiyuanYao TianyuanRisacher Shannon LZhang PanpanSchilling Kurt GLee Annie JBrickman Adam MMayeux RichardMez Jesse Kukull WalterBiber Sarah ALandman Bennett ABendlin Barbara BJohnson Sterling CSchneider JulieBarnes Lisa LBennett David ASaykin Andrew JCuccaro Michael LHohman Timothy JJefferson Angela LArcher Derek B - Triple-negative breast cancer (TNBC) is an aggressive subtype lacking effective treatment options, and paclitaxel resistance remains a major clinical challenge. This study investigated the role of VASN in mediating paclitaxel resistance in TNBC by integrating transcriptomic and single-cell RNA sequencing data from public databases and clinical samples. Using paclitaxel-resistant TNBC cell lines (MDA-MB-231R and CAL-51R) and xenograft models, we revealed that VASN was significantly upregulated in resistant TNBC cells and tissues, correlating with poor prognosis. Mechanistically, CEBPB directly bound to the VASN promoter to activate its transcription, and VASN interacted with IGF2BP3 via its LRR domain, recruiting USP10 to deubiquitinate and stabilize IGF2BP3 by suppressing K48-linked polyubiquitination. Stabilized IGF2BP3 enhanced ABCB1 expression through mA-dependent mRNA stabilization, activating the PI3K/AKT pathway and driving paclitaxel resistance. Genetic or pharmacological inhibition of VASN resensitized resistant cells to paclitaxel, and computational drug screening identified Trametinib as a candidate to downregulate VASN. Trametinib synergized with paclitaxel to effectively suppress tumor growth without obvious toxicity in resistant models. In summary, we uncovered a new CEBPB-VASN/IGF2BP3/USP10-ABCB1 axis responsible for paclitaxel resistance in TNBC. Targeting VASN with Trametinib in combination with paclitaxel represents a promising therapeutic strategy to overcome chemoresistance, offering a rationale for precision medicine in resistant TNBC. - Source: PubMed
Publication date: 2026/07/13
Liu HaoLu ZexiuChen MaoshanLi ZhenghangChen JianYang XingyuWan XueyingTu GangLiu ManranTang Lingfeng - To investigate whether the treatment effect of extended-release buprenorphine (BUP-XR) on opioid-free days in opioid use disorder (OUD) is mediated by reductions in opioid craving and improvements in personal functioning. - Source: PubMed
Publication date: 2026/07/01
Marsden JohnKelleher MikeCowden FionaDay EdwardDewhurst JonathanEvans RachelGilvarry EilishLowry NatalieMitcheson LukeMurray RobertQuarshie SophieHoare Zoë